SUPPRESSION OF LACTATION WITH LISURIDE

The influence of lisuride, a new semisynthetic ergot derivative, was investigated in women during the puerperium. Treatment with 600 or 900 Mg lisuride over 14 days (each test group n = 25) caused an immediate drop of the elevated prolactin (PRL) levels in all patients in comparison to values seen in normal, nonpregnant women (< 30 ng/ml). Such a sharp decline was not seen in two control groups of puerperal patients, nursing as well as nonnursing, placebo-treated women. The clinical efficacy in preventing or suppressing lactation was clear cut and comparable to the known PRL lowering effect of bromo-cryptinc. Severe side effects were not observed during lisuride treatment with these dosages. The postsuckling PRL increase was abolished by a single oral dose of lisuride (100. 200, 300 /jg), similar to that seen with bromocryptine (2.5 mg). The inhibition was dose dependent. Only doses of 200 and 300 ng showed, in comparison to a placebo group, a significant long-lasting (> 8 h) suppression of PRL secretion. © 1979 S. Karger AG, Basel.